ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Results of UNOS Survey on Diagnosis, Treatment and Follow-Up Evaluation of Clinical and Sub-Clinical TCMR and ABMR in Kidney Transplant Recipients

P. Sood,1 W. Cherikh,2 A. Toll,2 R. Mehta,1 C. Puttarajappa,1 S. Hariharan.1

1University of Pittsburgh Medical Center, Pittsburgh
2UNOS, Richmond.

Meeting: 2018 American Transplant Congress

Abstract number: D196

Keywords: Kidney transplantation

Session Information

Session Name: Poster Session D: Kidney: Acute Cellular Rejection

Session Type: Poster Session

Date: Tuesday, June 5, 2018

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall 4EF

Management strategies for treatment of rejection post ktx vary among centers. Controlling minor degrees of inflammation can prevent chronic allograft scarring. To study the diverse practices, a national survey of program directors was sent through UNOS to all kidney programs in US. Of the 77 responders, 47 were nephrologists and 30 were surgeons. Of the centers that responded, 31 performed >100 transplants during 8/2016-7/2017. The use of thymo, Basiliximab or Campath for induction was reported in 83%, 46% and 21% of the centers, respectively. 64% responders do rapid steroid withdrawal while 36% do not. 62% responders reported the use Belatacept in select cases. MPA is the major anti-metabolite (99%). Fifty percent of responders who used basiliximab reported TCMR and ABMR rates of 5-10%. For diagnosing TCMR, 97% used indication biopsy, 26% used protocol biopsy, 3% used serum biomarkers and none used urine cytokines. For ABMR, 95% used indication biopsy, 35% used protocol biopsy, 74% used DSA, 20% used C1q positive DSA and none used gene profiling (ENDATS). The reported treatment of subclinical borderline TCMR included iv/PO steroids (20%/13%), increased baseline IS (17%) or no treatment (8%). There was an increased trend for use of Bortezomib from C4D- to C4D+ABMR. For recurrent ABMR, Bortezomib use increased to 39% and Eculizumab use tripled to 21%.

C4D-ABMR (N=77) % C4D+ABMR (N=77)% Recurrent ABMR (N=77)%
IVIG/PE 53 53 47
IVIG/PE/Ritux 47 62 66
Bortezomib 18 27 39
Eculizumab 7 7 21
Increase BL IS 52 57 48

Most centers rely on renal function and f/u bx to ascertain resolution of rejection.

TCMR resolution% ABMR resolution%
Renal function 91 88
f/u bx 40 53
serum/ur biomarker 7 23
gene profiling 3 3

Survey reveals i) diverse management practices for rejection ii) Most rely on indication biopsy for diagnosing TCMR and ABMR, iii) Renal functions and f/u biopsy are used to document resolution of rejection, iii) Urinary cytokines and gene array analysis are rarely used. Standardization of practices for management of TCMR and ABMR is necessary and will give an opportunity to pool data for evaluating clinical outcomes.

CITATION INFORMATION: Sood P., Cherikh W., Toll A., Mehta R., Puttarajappa C., Hariharan S. Results of UNOS Survey on Diagnosis, Treatment and Follow-Up Evaluation of Clinical and Sub-Clinical TCMR and ABMR in Kidney Transplant Recipients Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Sood P, Cherikh W, Toll A, Mehta R, Puttarajappa C, Hariharan S. Results of UNOS Survey on Diagnosis, Treatment and Follow-Up Evaluation of Clinical and Sub-Clinical TCMR and ABMR in Kidney Transplant Recipients [abstract]. https://atcmeetingabstracts.com/abstract/results-of-unos-survey-on-diagnosis-treatment-and-follow-up-evaluation-of-clinical-and-sub-clinical-tcmr-and-abmr-in-kidney-transplant-recipients/. Accessed May 25, 2025.

« Back to 2018 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences